These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 18426581)

  • 21. Sex and ESR1 genotype may influence the response to treatment with donepezil and rivastigmine in patients with Alzheimer's disease.
    Scacchi R; Gambina G; Broggio E; Corbo RM
    Int J Geriatr Psychiatry; 2014 Jun; 29(6):610-5. PubMed ID: 24150894
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Acetylcholinesterase inhibitors for dementia--an update].
    Anghelescu I; Heuser I
    MMW Fortschr Med; 2007 May; 149 Suppl 2():76-8. PubMed ID: 17724973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: interim results.
    Amenta F; Carotenuto A; Fasanaro AM; Rea R; Traini E
    J Neurol Sci; 2012 Nov; 322(1-2):96-101. PubMed ID: 22959283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine].
    Sicras-Mainar A; Vergara J; Leon-Colombo T; Febrer L; Rejas-Gutierrez J
    Rev Neurol; 2006 Oct 16-31; 43(8):449-53. PubMed ID: 17033976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Noncognitive symptoms and long-term treatment expectations for Alzheimer disease.
    Blesa R
    Alzheimer Dis Assoc Disord; 2004; 18 Suppl 1():S9-16. PubMed ID: 15249843
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Switching cholinesterase inhibitor therapy in Alzheimer's disease--donepezil to rivastigmine, is it worth it?
    Bullock R; Connolly C
    Int J Geriatr Psychiatry; 2002 Mar; 17(3):288-9. PubMed ID: 11921158
    [No Abstract]   [Full Text] [Related]  

  • 27. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
    Di Santo SG; Prinelli F; Adorni F; Caltagirone C; Musicco M
    J Alzheimers Dis; 2013; 35(2):349-61. PubMed ID: 23411693
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease.
    Gauthier S; Feldman H; Hecker J; Vellas B; Emir B; Subbiah P;
    Curr Med Res Opin; 2002; 18(6):347-54. PubMed ID: 12442882
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
    Bullock R; Touchon J; Bergman H; Gambina G; He Y; Rapatz G; Nagel J; Lane R
    Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.
    Takeda A; Loveman E; Clegg A; Kirby J; Picot J; Payne E; Green C
    Int J Geriatr Psychiatry; 2006 Jan; 21(1):17-28. PubMed ID: 16323253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Donepezil provides greater benefits in mild compared to moderate Alzheimer's disease: implications for early diagnosis and treatment.
    Molinuevo JL; Berthier ML; Rami L
    Arch Gerontol Geriatr; 2011; 52(1):18-22. PubMed ID: 19948364
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease.
    Johannsen P; Salmon E; Hampel H; Xu Y; Richardson S; Qvitzau S; Schindler R;
    CNS Drugs; 2006; 20(4):311-25. PubMed ID: 16599649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease.
    Jones RW; Soininen H; Hager K; Aarsland D; Passmore P; Murthy A; Zhang R; Bahra R
    Int J Geriatr Psychiatry; 2004 Jan; 19(1):58-67. PubMed ID: 14716700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment.
    Wattmo C; Wallin ÅK; Londos E; Minthon L
    Alzheimer Dis Assoc Disord; 2011; 25(1):63-72. PubMed ID: 20847636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.
    Rodda J; Morgan S; Walker Z
    Int Psychogeriatr; 2009 Oct; 21(5):813-24. PubMed ID: 19538824
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Drug-cholinesterase-inhibitors persistence patterns in treated patients with dementia of Alzheimer type: retrospective comparative analysis of donepezil, rivastigmine and galantamine].
    Sicras A; Rejas-Gutiérrez J
    Rev Neurol; 2004 Aug 16-31; 39(4):312-6. PubMed ID: 15340887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The estimation of premorbid intelligence levels in French speakers].
    Mackinnon A; Mulligan R
    Encephale; 2005; 31(1 Pt 1):31-43. PubMed ID: 15971638
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sustained cognitive improvement following treatment of Alzheimer's disease with donepezil.
    Evans M; Ellis A; Watson D; Chowdhury T
    Int J Geriatr Psychiatry; 2000 Jan; 15(1):50-3. PubMed ID: 10637404
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comments on Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil.
    McRae TD; Schwam EM
    Curr Med Res Opin; 2002; 18(6):i-iii; author reply iv-vi. PubMed ID: 12442885
    [No Abstract]   [Full Text] [Related]  

  • 40. Current treatments of Alzheimer disease: are main caregivers satisfied with the drug treatments received by their patients?
    Sevilla C; Jiménez Caballero PE; Alfonso V; González-Adalid M
    Dement Geriatr Cogn Disord; 2009; 28(3):196-205. PubMed ID: 19738386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.